findmyKOL

Jeffrey Yorio, MD

Basic profile

Hematology / Oncology

ORCIDNPI
RegionAustin, TX · South CentralSpecialtyHematology / OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Jeffrey Yorio is an Oncology physician. OpenAlex indexes 36 publications with 4,144 citations (h-index 11).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
36publications

Distinct works indexed by OpenAlex, matched via ORCID.

4,144citations

Total citations across indexed works.

11h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
25companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

6204 Balcones Dr
Austin, TX 787314214

Telephone

512-427-9400

Registry record last updated 15 Nov 2017.

View the NPPES registry record

Industry payments

25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    37.3%
    PD-1 inhibitor16.6%
    Pembrolizumab100%
    Part B, office-administered26 patients
    Platinum-based Drug10.9%
    Oxaliplatin96%Carboplatin4%
    Part B, office-administered25 patients

    + 14 more classes in this area

  • Blood & clotting

    32%
    Erythropoiesis-stimulating Agent23.7%
    Darbepoetin alfa100%
    Part B, office-administered15 patients
    Parenteral Iron Replacement8%
    Iron sucrose100%
    Part B, office-administered15 patients

    + 3 more classes in this area

  • Metabolism & gastrointestinal

    21.4%
    Other antiemetics17.8%
    Fosaprepitant100%
    Part B, office-administered45 patients
    Serotonin-3 Receptor Antagonist2.7%
    Palonosetron hcl57%Granisetron hydrochloride40%Ondansetron Odt3%Ondansetron Hcl1%
    Part D + Part B56 patients

    + 6 more classes in this area

Where care is delivered (Part B)0.1% facility · 99.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”